Merck, Inc.
🇵🇭Philippines
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 843
- Registration Number
- NCT00337428
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 190
- Registration Number
- NCT00337610
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 848
- Registration Number
- NCT00337727
MK0354 Clinical Efficacy and Tolerability Study (0354-004)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT00337415
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 151
- Registration Number
- NCT00335075
Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00330395
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1800
- Registration Number
- NCT00326183
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1042
- Registration Number
- NCT00325130
MK0859 Dose-Ranging Study (0859-003)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT00325455
Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 566
- Registration Number
- NCT00322361
© Copyright 2024. All Rights Reserved by MedPath